Zoya Gluzman-Poltorak, Ph.D., MBA, is the CEO and Co-Founder of Forta Bio, a City of Hope spinout developing ODCs™ (Oligonucleotide-Dependent Cytotoxicity therapeutics)- a new class of precision DNA therapeutics that selectively eliminate TERT-positive pathogenic cells and modulate immune pathways. With 25+ years in biotech, she has led gene, cell, protein, and oligonucleotide programs at Neumedicines, ASC Therapeutics, SonoThera, and others, advancing 7 INDs and securing over $250M in BARDA, DoD, NIH, and venture funding. At Forta, she is driving ODC™ platform development and leading ongoing fundraising to accelerate IND-enabling studies and pipeline expansion.